Gastrointestinal Cancers

KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy.

Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile.

Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer.

Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement.

Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer.

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer.

Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer.

An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma.

Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study.

A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers.